HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer

Abstract

Gemcitabine has limited clinical benefits for pancreatic cancer patients. The phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway is important in cell proliferation and survival, and is frequently dysregulated in pancreatic cancer. To obtain insights into novel therapeutic strategies for treating pancreatic cancer, we investigated whether HS-104, a novel PI3K inhibitor, in combination with gemcitabine would show a synergistic effect in pancreatic cancer. We first evaluated the effect of gemcitabine alone or in combination with HS-104 on cell viability. When administered together, the two drugs synergistically inhibited the viability of AsPC-1 and PANC-1 cells, and decreased mitochondrial membrane potential, thereby inducing apoptosis. Compared to the treatment with either drug alone, the combination treatment resulted in apoptosis accompanied by increased levels of cleaved caspase-3 and Bax. These results were consistent with decreased expression of p-Akt, p-mTOR, p-Mek and p-Erk. Moreover, the combination treatment inhibited blood vessel formation in a Matrigel plug assay in mice. Furthermore, in vivo, the combination significantly inhibited tumor growth and enhanced apoptosis by increasing the number of TUNEL-positive cells, and cleaved caspase-3 together with decreasing the expression of angiogenesis- and proliferation-related effectors such as CD34 and PCNA in tumor tissues, compared with each drug alone. Taken together, our study demonstrates that the combination of gemcitabine and HS-104 had a synergistic anticancer effect and inhibited the PI3K/Akt and RAF/Mek pathways on pancreatic cancers. On the basis of our results, we suggest that the combination of these two drugs may be considered as a new therapeutic regimen for treating pancreatic cancer.

miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway

“…PI3K is a membrane protein related to G protein-coupled receptors (42). PI3K activation triggers a series of intracellular events leading to the activation of Akt and mTOR (43)(44)(45), which thereafter induces the expression of multiple target genes that regulate cell proliferation, differentiation and other funtions (46,47). Our results revealed that the PI3K/Akt/mTOR pathway was involved in the invasion and metastasis of colon cancer cells, which was negatively regulated by miR-218.…”

Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway

“…Interestingly, gemcitabine at both concentrations upregulated both PI3K gene and protein expression. Inhibition of PI3K was shown to enhance the chemosensitivity of gemcitabine (Jung et al, 2014;Mao et al, 2018b). DAPT was also shown to inhibit PI3K and suppress CCA cell invasion, migration, metastasis, and epithelial-mesenchymal transition (EMT) (Peng et al, 2020).…”

Inmunología del cáncer II: bases moleculares y celulares de la carcinogénesis

“…Se han considerado abordajes como la inhibición de la unión entre el VEGF-A y su receptor con el uso del anticuerpo monoclonal humanizado bevasizumab, registrado para el tratamiento pasivo del cáncer de ovario, el cáncer de colon metastásico, el cáncer renal, los glioblastomas y algunas variantes de cáncer de pulmón (70) . Adicionalmente, se ha ensayado la inhibición de la ruta PI3K-Akt en combinación con quimioterapia, con evidencias de reducción de angiogénesis en modelos experimentales preclínicos (71) .…”